What Is the CADTH Reimbursement Recommendation for Ledaga?: CADTH recommends that Ledaga should not be reimbursed by public drug plans for the treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in adult patients who have received prior skin-directed therapy.
Why Did CADTH Make This Recommendation?:
Although evidence from a clinical trial found that Ledaga was not inferior to chlormethine ointment, chlormethine ointment is not used in Canada. There was no evidence to show whether Ledaga works better than or similar to treatments for MF-CTCL that are currently used in Canada.
There is an unmet need for treatments with fewer side effects, but it remains unknown whether Ledaga has fewer side effects compared with other treatments for MF-CTCL used in Canada.
What is Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma?: MF-CTCL is a type of blood cancer that starts in the skin with visible patches and plaques which are associated with itchiness, pain, or burning. It is estimated that every year there are 5.6 new cases of MF-CTCL per million persons.
Unmet Needs in Mycosis Fungoides-Type Cutaneous T-Cell Lymphoma: Currently, treatments for MF-CTCL work in most but not all patients, and long-term use may cause side effects. Phototherapy is one of the treatments for MF-CTCL, but it is difficult to access for many patients. Unmet needs for patients with MF-CTCL include treatments that can cure MF-CTCL, are easily accessible, and have fewer side effects.
How Much Does Ledaga Cost?: Treatment with Ledaga is expected to cost approximately $2,995 per month.
Copyright © 2021 Canadian Agency for Drugs and Technologies in Health.